Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.051 -- 00:00:03.392 Hello and welcome to VEER Biotechnology's 00:00:03.392 -- 00:00:05.533 second quarter 2026 00:00:05.533 -- 00:00:08.995 financial results and corporate update conference call. 00:00:08.995 -- 00:00:11.916 As a reminder, this call is being recorded. 00:00:11.916 -- 00:00:15.457 At this time, all participants are in the listen-only mode. 00:00:15.457 -- 00:00:19.819 After the speaker's prepared remarks, there will be a question-and-answer session. 00:00:19.819 -- 00:00:23.881 I will now turn the call over to Kiki Patel, Head of Investor Relations. 00:00:23.881 -- 00:00:26.601 You may begin, Kiki. 00:00:27.662 -- 00:00:30.044 Thank you, Operator, and welcome, everyone. 00:00:30.044 -- 00:00:34.948 Earlier today, we issued a press release reporting our second quarter 2026 financial 00:00:34.948 -- 00:00:39.532 results and corporate update. Before we begin, I would like to remind everyone that some 00:00:39.532 -- 00:00:42.995 of the statements we are making today are forward-looking statements under applicable 00:00:42.995 -- 00:00:48.079 securities laws. These forward-looking statements involve substantial risks and uncertainties 00:00:48.079 -- 00:00:53.203 that could cause our clinical development programs, collaboration outcomes, future results, 00:00:53.203 -- 00:00:57.767 performance, or achievements to differ significantly from those expressed or implied 00:00:57.767 -- 00:01:02.363 in such forward-looking statements. More looking statements include but are not limited 00:01:02.363 -- 00:01:06.064 to statements regarding the potential for new therapies to improve awareness, testing, 00:01:06.064 -- 00:01:10.645 and access to care for the chronic hepatitis delta community, the therapeutic and commercial 00:01:10.645 -- 00:01:16.1...